Vaccine and Drug Development, page-7

I reread Charlie's article tonight and I had overlooked some information.

https://themedicinemaker.com/manufacture/eliminating-bioconjugation-roadblocks

vaccine and drug development !!! Derek said we were only involved in vaccine quality control?


"Confidence in such bioconjugation tools can also be derived from the growing catalog of diagnostic and therapeutic R&D efforts that have been made possible by these novel binding technologies. Adiponectin immunosensor development, tumor cell isolation, and extracellular vesicle research are just a few examples of the research areas benefiting from this approach. "

we have been working on these for a while and have publication on all 3 on our webpage.

https://www.anteotech.com/life-science/anteobind/publications/

why I revisited the article was because I saw this from Merck

Antibody-drug conjugates (ADCs) are an emerging class of medicines designed for high-specificity targeting and destruction of cancer cells while preserving healthy cells.

https://www.linkedin.com/posts/merc...ugates-adcs-activity-6807939340547715072-41jK


then reading the article we have this

"A recent study used the technology to conjugate recombinant Spike RBD of selected SARS-CoV-2 variants. It sought to understand the impact of COVID-19 vaccination on the levels of neutralizing antibodies against these RBD variants, and demonstrated that the nanosized molecular glue approach to bioconjugation provides a rapid and effective tool for SARS-CoV-2 multiplex immunoassay development for vaccine study (1)."

from the study

https://www.medrxiv.org/content/10.1101/2021.03.08.21252958v1

"The SARS-CoV-2 pandemic virus is consistently evolving with mutations within the receptor binding domain (RBD)¹ being of particular concern^2-4. To date, there is little research into protection offered following vaccination or infection against RBD mutants in emerging variants of concern (UK³, South African⁵, Mink⁶ and Southern California⁷). To investigate this, serum and saliva samples were obtained from groups of vaccinated (Pfizer BNT-162b2⁸), infected and uninfected individuals."
Bead coupling

Coupling of RBD mutant antigens was done by Anteo coupling (#A-LMPAKMM-10, Anteo Tech Reagents) following the manufacturer’s instructions. Briefly, 100 μL of spectrally distinct populations of MagPlex beads (1.25×10⁶) (Luminex) were activated in 100 μL of AnteoBind Activation Reagent for 1 hour at room temperature.


I think  management are involved in a lot of projects that we will be hearing about!!! we aren't just relying on our covid test. add batteries, contract services, raw materials ,drug and vaccine development to a growing list of future revenue possibilities.....